News & events News Solid Biosciences announce FDA have removed clinical hold from their gene therapy trial Solid Biosciences have announced that the FDA has given approval for the company to restart the phase I/II IGNITE DMD clinical trial. The clinical trial, which aims to test the safety and effectiveness of a potential treatment called SGT-001, was placed on hold after the first person to receive the potential drug experienced unexpected side effects. SGT-001 uses a harmless virus to deliver a functional copy of the dystrophin gene to cells. However, since the gene is so large – too big to be carried by the virus – researchers have developed smaller genes that can produce smaller but functional versions of the dystrophin protein (called microdystrophin). By using a virus that preferentially infects muscle cells, researchers hope to be able to restore some dystrophin production where it is needed most. The clinical trial of the micro-dystrophin carrying virus will now continue to recruit participants (approximately 16) in Florida and will use a slightly changed . To learn more about the trial design, you can read more in Solid Biosciences’ letter to the community here.